Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Polyclonal anti-T-cell therapy for type 1 diabetes mellitus of recent onset.

Saudek F, Havrdova T, Boucek P, Karasova L, Novota P, Skibova J.

Rev Diabet Stud. 2004 Summer;1(2):80-8. Epub 2004 Aug 10.

2.

Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial.

Gitelman SE, Gottlieb PA, Rigby MR, Felner EI, Willi SM, Fisher LK, Moran A, Gottschalk M, Moore WV, Pinckney A, Keyes-Elstein L, Aggarwal S, Phippard D, Sayre PH, Ding L, Bluestone JA, Ehlers MR; START Study Team.

Lancet Diabetes Endocrinol. 2013 Dec;1(4):306-16. doi: 10.1016/S2213-8587(13)70065-2. Epub 2013 Aug 28.

PMID:
24622416
3.

Antithymocyte globulin therapy for patients with recent-onset type 1 diabetes: 2 year results of a randomised trial.

Gitelman SE, Gottlieb PA, Felner EI, Willi SM, Fisher LK, Moran A, Gottschalk M, Moore WV, Pinckney A, Keyes-Elstein L, Harris KM, Kanaparthi S, Phippard D, Ding L, Bluestone JA, Ehlers MR; ITN START Study Team.

Diabetologia. 2016 Jun;59(6):1153-61. doi: 10.1007/s00125-016-3917-4. Epub 2016 Apr 6.

4.

Anti-thymocyte globulin/G-CSF treatment preserves β cell function in patients with established type 1 diabetes.

Haller MJ, Gitelman SE, Gottlieb PA, Michels AW, Rosenthal SM, Shuster JJ, Zou B, Brusko TM, Hulme MA, Wasserfall CH, Mathews CE, Atkinson MA, Schatz DA.

J Clin Invest. 2015 Jan;125(1):448-55. doi: 10.1172/JCI78492. Epub 2014 Dec 15.

5.

Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Diabète Insuline Orale group.

Chaillous L, Lefèvre H, Thivolet C, Boitard C, Lahlou N, Atlan-Gepner C, Bouhanick B, Mogenet A, Nicolino M, Carel JC, Lecomte P, Maréchaud R, Bougnères P, Charbonnel B, Saï P.

Lancet. 2000 Aug 12;356(9229):545-9.

PMID:
10950231
6.

Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial.

Rigby MR, DiMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE, Patel CM, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi SM, Raskin P, Moran A, Russell WE, Pinckney A, Keyes-Elstein L, Howell M, Aggarwal S, Lim N, Phippard D, Nepom GT, McNamara J, Ehlers MR; T1DAL Study Team.

Lancet Diabetes Endocrinol. 2013 Dec;1(4):284-94. doi: 10.1016/S2213-8587(13)70111-6. Epub 2013 Sep 23.

7.

Therapy with the hsp60 peptide DiaPep277 in C-peptide positive type 1 diabetes patients.

Huurman VA, Decochez K, Mathieu C, Cohen IR, Roep BO.

Diabetes Metab Res Rev. 2007 May;23(4):269-75.

PMID:
17024692
8.

High-dose intravenous insulin infusion versus intensive insulin treatment in newly diagnosed IDDM.

Schnell O, Eisfelder B, Standl E, Ziegler AG.

Diabetes. 1997 Oct;46(10):1607-11.

PMID:
9313757
9.

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.

Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L, Hale G, Gorus F, Goldman M, Walter M, Candon S, Schandene L, Crenier L, De Block C, Seigneurin JM, De Pauw P, Pierard D, Weets I, Rebello P, Bird P, Berrie E, Frewin M, Waldmann H, Bach JF, Pipeleers D, Chatenoud L.

N Engl J Med. 2005 Jun 23;352(25):2598-608.

10.

Treatment of new-onset type 1 diabetes with peptide DiaPep277 is safe and associated with preserved beta-cell function: extension of a randomized, double-blind, phase II trial.

Raz I, Avron A, Tamir M, Metzger M, Symer L, Eldor R, Cohen IR, Elias D.

Diabetes Metab Res Rev. 2007 May;23(4):292-8.

PMID:
17124720
11.

Effect of cholecalciferol as adjunctive therapy with insulin on protective immunologic profile and decline of residual β-cell function in new-onset type 1 diabetes mellitus.

Gabbay MA, Sato MN, Finazzo C, Duarte AJ, Dib SA.

Arch Pediatr Adolesc Med. 2012 Jul 1;166(7):601-7. doi: 10.1001/archpediatrics.2012.164.

PMID:
22751874
12.

Low dose linomide in Type I juvenile diabetes of recent onset: a randomised placebo-controlled double blind trial.

Coutant R, Landais P, Rosilio M, Johnsen C, Lahlou N, Chatelain P, Carel JC, Ludvigsson J, Boitard C, Bougnères PF.

Diabetologia. 1998 Sep;41(9):1040-6.

PMID:
9754822
13.

Insulin requirements and residual beta-cell function 12 months after concluding immunotherapy in type I diabetic patients treated with combined azathioprine and thymostimulin administration for one year.

Moncada E, Subirá ML, Oleaga A, Goñi F, Sánchez-Ibarrola A, Monreal M, Sevilla M, Goñi MJ, Yoldi A, Terán D, et al.

J Autoimmun. 1990 Oct;3(5):625-38.

PMID:
2252531
14.
15.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
16.

Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.

Dejgaard TF, Frandsen CS, Hansen TS, Almdal T, Urhammer S, Pedersen-Bjergaard U, Jensen T, Jensen AK, Holst JJ, Tarnow L, Knop FK, Madsbad S, Andersen HU.

Lancet Diabetes Endocrinol. 2016 Mar;4(3):221-32. doi: 10.1016/S2213-8587(15)00436-2. Epub 2015 Dec 3.

PMID:
26656289
17.

Combination of nicotinamide and steroid versus nicotinamide in recent-onset IDDM. The IMDIAB II Study.

Pozzilli P, Visalli N, Boccuni ML, Baroni MG, Buzzetti R, Fioriti E, Signore A, Cavallo MG, Andreani D, Lucentini L, et al.

Diabetes Care. 1994 Aug;17(8):897-900.

PMID:
7956639
18.

Beta-cell response to intravenous glucagon in African-American and Hispanic children with type 2 diabetes mellitus.

Taha DR, Castells S, Umpaichitra V, Bastian W, Banerji MA.

J Pediatr Endocrinol Metab. 2002 Jan;15(1):59-67.

PMID:
11822582
19.

Residual beta cell function in newly diagnosed type 1 diabetes after treatment with atorvastatin: the Randomized DIATOR Trial.

Martin S, Herder C, Schloot NC, Koenig W, Heise T, Heinemann L, Kolb H; DIATOR Study Group.

PLoS One. 2011 Mar 11;6(3):e17554. doi: 10.1371/journal.pone.0017554.

20.

A randomized trial of nicotinamide and vitamin E in children with recent onset type 1 diabetes (IMDIAB IX).

Crinò A, Schiaffini R, Manfrini S, Mesturino C, Visalli N, Beretta Anguissola G, Suraci C, Pitocco D, Spera S, Corbi S, Matteoli MC, Patera IP, Manca Bitti ML, Bizzarri C, Pozzilli P; IMDIAB group.

Eur J Endocrinol. 2004 May;150(5):719-24.

Supplemental Content

Support Center